ERBB2 and ductal breast carcinoma in situ: In this earlier study, DCIS with HER2/neu+/Ki67+ expression was associated with a higher risk of DCIS recurrence (univariate HR=1.9, 95% CI: 1.0–3.5) but was not associated with the development of invasive recurrence.